Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03465891 Terminated - Lymphoma Clinical Trials

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Start date: March 9, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety and effects of atezolizumab with low dose radiation on people with relapsed or refractory follicular lymphoma, In this study, the patient will get either atezolizumab with low dose radiation or, atezolizumab alone. To be better, the atezolizumab and low dose radiation should increase life by 1 year or more compared to the usual approach.

NCT ID: NCT03460977 Recruiting - Clinical trials for Follicular Lymphoma (FL)

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Start date: April 17, 2018
Phase: Phase 1
Study type: Interventional

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

NCT ID: NCT03458728 Terminated - Neuroblastoma Clinical Trials

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Start date: April 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

NCT ID: NCT03458546 Completed - Lymphoma, B-Cell Clinical Trials

Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

This study is a phase Ib, single arm, open label clinical trial that will enroll patients with untreated diffuse large B-cell lymphoma (DLCBL) at moderate or high risk for poor outcome

NCT ID: NCT03458520 Recruiting - Lymphoma Clinical Trials

Pediatric PET/MR Image Registry

Start date: February 1, 2018
Phase:
Study type: Observational

The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.

NCT ID: NCT03458260 Active, not recruiting - Clinical trials for Aggressive Non-Hodgkin Lymphoma

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Start date: March 26, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

NCT ID: NCT03456726 Completed - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Start date: April 9, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.

NCT ID: NCT03456466 Recruiting - Clinical trials for Non-hodgkin's Lymphoma

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Start date: May 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-∞); The time to reach the maximum plasma concentration after treatment (Tmax) Total clearance (CL); Elimination of half-life (t1 / 2); Apparent distribution volume (Vd).

NCT ID: NCT03454945 Recruiting - Lymphoma Clinical Trials

Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides

Start date: March 1, 2017
Phase: Phase 3
Study type: Interventional

Current study aims at assessing the efficacy of doxycycline as a potential treatment modality for early stages of MF.

NCT ID: NCT03452774 Recruiting - Breast Cancer Clinical Trials

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.